Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Eli Lilly Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (71)
Cancellation by sponsor (67)
Australian public assessment report (AusPar) (20)
Prescription medicine registration (20)
Designation or determination (4)
Prescription medicine evaluation (4)
Prescription medicine decision summary (3)

Date

2025 (30)
2024 (21)
2023 (21)
2022 (15)
2021 (10)
2020 (4)
2019 (34)
2018 (14)
2017 (1)
2016 (2)
2015 (7)
2014 (2)
2013 (4)
2012 (1)
2011 (2)
2010 (1)
2008 (2)
2007 (1)
2006 (1)
2004 (1)
2002 (2)
1999 (4)
1998 (1)
1996 (2)
1992 (4)
1991 (2)

Search

Sponsor content

189 result(s) found, displaying 91 to 100

EMGALITY galcanezumab 120mg/mL prefilled pen (302146)

28 May 2019

ARTG

Australian Register of Therapeutic Goods (ARTG) information for EMGALITY galcanezumab 120mg/mL prefilled pen.
EMGALITY galcanezumab 120mg/mL prefilled syringe (302145)

28 May 2019

ARTG

Australian Register of Therapeutic Goods (ARTG) information for EMGALITY galcanezumab 120mg/mL prefilled syringe.
TALTZ (Eli Lilly Australia Pty Ltd)

28 May 2021

Prescription medicine registration

Active ingredients: ixekizumab.
AusPAR: Baricitinib

20 May 2021

Australian public assessment report (AusPar)

Australian Public Assessment Report for Baricitinib
EFFIENT prasugrel (as hydrochloride) 5 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

20 May 2021

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
EFFIENT prasugrel (as hydrochloride) 10 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

20 May 2021

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
ANDEPRA duloxetine 60 mg (as hydrochloride) enteric capsule blister pack Cancelled under Section 30(1)(c) of the Act

14 May 2021

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
ANDEPRA duloxetine 30 mg (as hydrochloride) enteric capsule blister pack Cancelled under Section 30(1)(c) of the Act

14 May 2021

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
VERZENIO abemaciclib 100 mg tablet blister pack (304767)

8 April 2019

ARTG

Australian Register of Therapeutic Goods (ARTG) information for VERZENIO abemaciclib 100 mg tablet blister pack.
VERZENIO abemaciclib 150 mg tablet blister pack (304766)

8 April 2019

ARTG

Australian Register of Therapeutic Goods (ARTG) information for VERZENIO abemaciclib 150 mg tablet blister pack.

Pages

First page
Previous page
…
Page 6
Page 7
Page 8
Page 9
Current page 10
Page 11
Page 12
Page 13
Page 14
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.